Mengke Pharmaceutical (688373.SH) announced that the company recently received a notice from the National Medical Products Administration regarding MRX...
According to the Zhitong Caijing APP, Mengke Pharmaceuticals (688373.SH) announced that the company recently received a "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for MRX-5 tablets used in the treatment of infections caused by non-tuberculous mycobacteria sensitive to this product. The announcement shows that MRX-5 is a new type of benzo-borazole class antibiotic intended for the treatment of mycobacterial infections, particularly those caused by NTM.